Background {#Sec1}
==========

Coronary heart disease (CHD) remains one of the major causes of mortality worldwide, even though great progress has been made in the development of novel therapeutic approaches. Pathological mechanisms of CHD have been the focus of research and it's believed that lipid infiltration and inflammation contribute to CHD progress \[[@CR1], [@CR2]\]. The corresponding anti-inflammatory and lipid-lowering drugs have been widely applied in the management of CHD \[[@CR3]--[@CR5]\].

According to lipid infiltration theory of CHD, abnormal deposition of lipid in subendothelial layer of artery causes narrowing of coronary arteries, which will eventually lead to CHD \[[@CR6]\]. Studies have shown that high level of plasma low density lipoprotein (LDL) is an independent risk factor for CHD, whereas high level of high density lipoprotein (HDL) is inversely correlated with risk of CHD \[[@CR7], [@CR8]\]. Apolipoprotein A-I (ApoA-I) is the major protein component of HDL and is involved in the transport of cholesterol from circulatory system to the liver \[[@CR9]\]. Lipoprotein lipase (LPL) is the key enzyme in the catabolism of triglyceride. It breaks down triglycerides into free fatty acids (FFA), which provide 80 % of the energy consumed by cardiomyocytes \[[@CR10]\]. Plasma FFA are combined with fatty acid-binding protein (FABP) and transferred into cytoplasm of cardiac cells by cluster of differentiation 36 (CD36), and then further transported into mitochondria through carnitine, catalyzed by carnitinepalmitoyltransferase I (CPT-I) which is another key enzyme in fatty acid metabolism \[[@CR11], [@CR12]\]. FFA eventually undergo oxidation in mitochondria to produce ATP for heart contraction \[[@CR13], [@CR14]\].

In addition to lipid filtration, inflammation also contributes to the initiation and progression of CHD. Arachidonic acid (AA) mediated inflammation is thought to be the major cause of myocardial cell damage \[[@CR15]\]. Under inflammatory stimuli, phospholipase A2 (PLA2) hydrolyzes phospholipids in cell membranes and releases AA, which are further converted into active compounds catalyzed by different subtypes of cyclooxygenases (COXs). The major metabolic products of AA include prostaglandins (PGs), prostacyclin (PGI2) and thromboxanes (TXBs), which are involved in inflammatory responses \[[@CR16], [@CR17]\]. Therefore, inhibiting AA-mediated PLA2-COX pathway to protect cardiac cells against inflammatory injuries has become the strategy for the management of CHD \[[@CR18]\]. Nonsteroidal anti-inflammatory drugs (NSAIDs) have been widely used to treat patients with CHD. However, there has been an increasing number of reports about cardiotoxicities induced by NSAIDs \[[@CR19]\].

Peroxisome Proliferator activated receptors α (PPARα) has been found to play crucial roles in regulating lipid metabolism \[[@CR20], [@CR21]\]. Activation of PPARα reduces plasma level of very low density lipoprotein (VLDL) by inhibiting synthesis of triglyceride and cholesterol. PPARα also promotes plasma triglyceride clearance by mobilizing LPL activity and enhancing oxidation of fatty acids, thereby regulating plasma lipid levels \[[@CR22]\]. In addition, PPARα also exerts anti-inflammatory effect, mainly through inhibiting the activity of COX-2 and monocyte chemoattractant protein-1 (MCP-1) through NF-κB signaling pathway \[[@CR23], [@CR24]\]. Therefore, PPARα agonists are considered to be the promising new candidates for the treatment of CHD.

Traditional Chinese medicine has been applied in the treatment of CHD for thousands of years. DQP is one of the most widely prescribed formulas and has been shown to have remarkable protective effect on ischemia heart tissues \[[@CR25]\]. DQP is prepared from equal amounts of two dried Chinese herbs, *Salvia miltiorrhiza Bunge* and *Panax notoginseng (Burk.) F. H. Chen*. The major effective ingredients of *Salvia miltiorrhiza Bunge* and *Panax notoginseng (Burk.) F. H. Chen* are salvianolic acids and *panax notoginseng saponins* (PNS), respectively \[[@CR26], [@CR27]\]. DQP was widely produced in China in accordance with the China Pharmacopoeia standard of quality control, and was listed in Chinese Pharmacopoeia 2010 as routine drug in the clinical treatment of CHD \[[@CR28]\]. Until now, many studies have been conducted to investigate the effects of active monomers in DQP on CHD. PNS were found to inhibit ischemia-induced myocardial apoptosis and tanshinone IIA (monomer of *Salvia miltiorrhiza*) was found to have cardioprotective and anti-hypertrophic effects \[[@CR29], [@CR30]\]. Our previous studies proved that DQP had efficacy on CHD through regulating Renin-Angiotensin-Aldosterone System (RAAS) and lipid metabolism \[[@CR31], [@CR32]\]. However, the comprehensive effects of DQP on PPARα, lipid metabolism and inflammation pathway mediated by PLA2-COX-2 haven't been completely understood yet. In this study, we aim to investigate the effects of DQP on lipid metabolism and PLA2-COX-2 pathway, so as to uncover the pharmacological mechanisms of DQP and provide experimental basis for its clinical application.

Methods {#Sec2}
=======

Animals and grouping {#Sec3}
--------------------

Studies were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH Publications No. 85-23, revised 1996) the China Physiological Society's "Guiding Principles in the Care and Use of Animals" and with approval of the Animal Care Committee of Beijing Medical Center. A total of 80 male Sprague-Dawley (SD) rats (weighted 220 g ± 10 g) in Specific Pathogen Free (SPF) grade were selected (purchased from Beijing Vital River Laboratory Animal Technology Co.Ltd. License number: SCXK2010--2011).

Animal model preparation {#Sec4}
------------------------

Rats were randomly divided into four groups: sham group, model group, positive control group (control) and DQP group. CHD rat model with in vivo coronary left anterior descending (LAD) occlusion was then induced as described in our previous study \[[@CR32]\]. Briefly, left thoracotomy was performed after rats were anaesthetized by 1 % pentobarbital sodium at the dosage of 50 mg/kg. LAD coronary artery was then ligated with a 5-0 polypropylene suture. The thorax was closed with 2.0 absorbable silk surgical sutures as we previously reported after ligation. The sodium penicillin was given to prevent the potential wound inflammation for 3 days after surgery. Rats in sham group received the same procedures except that the coronary artery was not ligated. In addition, rats in model group, positive control group and DQP group were fed with high fat diet for 28 days while rats in sham group fed with normal diet. From the second day after operation, rats in DQP group were treated with DQP aqueous solution (Tongren tang, Beijing, China, Series: 6128006) at the daily dosage of 1.5 mg/kg via oral gavage for 28 consecutive days. Rats in positive control group received pravastatin (Bristol-Myers Squibb, China, Series: H19980197) aqueous solution at the daily dosage of 1.2 mg/kg. Animals in sham group and model group were given a gavage of normal saline water for 28 days. All animals were anaesthetized using pentobarbital sodium following an overnight fast at the end of study. Blood samples were collected via abdominal aorta puncture.

The overall mortality rate of rats during the entire experiment (28 days after surgery) was 22.5 %. Among them, 7 rats died during the surgery and 11 rats died the day after the surgery, probably due to acute pump failure or lethal arrhythmias, as they manifested serious clinical signs, such as short of breath and severe tachycardia.

Assessment of cardiac functions {#Sec5}
-------------------------------

Cardiac functions were assessed by echocardiography at 28d after surgery. Rats were anaesthetized before assessment. The parameters of heart functions include: left ventricular end-systolic diameter (LVESd), left ventricular end-diastolic diameter (LVEDd), ejection fraction (EF) and fractional shortening (FS). EF was calculated as follows: EF = \[(LVEDv − LVESv)/LVEDv\] × 100 %. FS was calculated using the equation: \[(LVEDd − LVESd)/LVEDd\] × 100 %.

Measurement of plasma TC, TG, LDL and HDL levels {#Sec6}
------------------------------------------------

Twenty eight days after surgery, animals were sacrificed after anaesthetization and blood was taken through abdominal aorta. The blood was centrifuged at 8000 g for 10 min and supernatant was used for detection of plasma indicators. Plasma levels of total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL) and low density lipoprotein (LDL) were measured by automatic biochemical analyzer (HITACH17080, Japan) following manufacturer's instructions. The cholesterol kit (COD-PAP Method), triglyceride kit (GPO-PAP Method), direct HDL kit and direct LDL kit were purchased from BiosinaTechnologies Inc.

Evaluation of mRNA expressions of molecules involved in lipid metabolism by polymerase chain reaction (PCR) {#Sec7}
-----------------------------------------------------------------------------------------------------------

Expressions of LPL and CD36 in heart tissues were determined by reverse transcriptase polymerase chain reaction (RT-PCR). Heart tissues near infarct zone were excised and frozen in liquid nitrogen. Total RNA was extracted using Trizol Reagent (Gibco-BRL, Paisley, UK). The concentration of RNA was measured by Nano Drop 2000 (Thermo Scientific, USA). RNA was transcribed using the RevertAidTM First Stand cDNASynthesis kit (Fermentas, LT). RNAs quantities of LPL, CD36 and GAPDH were analyzed by PCR. The reaction system contained 2 μl cDNA, 0.5 μl forward and reverse primers, 10 μl Rox and 7 μl DEPC water. PCR conditions were set as follows: 15 s at 95 °C for denaturation, 1 min at 55 °C for annealing and extension. 40 cycles of amplifications were performed for each gene. The sequences of the primers were shown at Table [1](#Tab1){ref-type="table"}. Quantities of LPL and CD36 mRNA were normalized to mRNA quantities of GAPDH.Table 1Nucleotide sequences of primers used in real-time PCRGene (accession no.)PrimesNucleotiede sequences5'-3'Length (bp)Temp (°C)LPLForwardCGCTCCATCCATCTCTTC57.3ReverseGGCTCTGACCTTGTTGAT15955.0CD36ForwardGGTCCTTACACATACAGAGT55.8ReverseCCACAGCCAGATTGAGAA16355.0GAPDHForwardTCAACGGCACAGTCAAG55.0ReverseTACTCAGCACCAGCATCA11655.0

Measurement of protein expressions detected by western blot {#Sec8}
-----------------------------------------------------------

The border of infarcted myocardium in left ventricle homogenates was prepared for the analysis of protein levels. Equal amounts of protein extracts (20 μg) were separated by 12.5 % or 15 % sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis (Bio-Rad, CA, U.S.A.) and transferred to nitrocellulose membranes electrophoretically (semidry transfer). Membranes were blocked with 5 % non-fat dry milk in Tris-buffered saline (20 mM Tris, pH 7.6, 137 mM NaCl) with 0.1 % Tween 20, washed, and then incubated with primary antibody. Primary antibodies employed included: goat polyclonal antiglyceraldehyde-3-phosphate dehydrogenase (GAPDH) and anti-ApoA-I, PPARα, FABP, CPT-1A, PLA2, COX-2, NF-κB and STAT3 (Anti-Apolipoprotein AIantibody, ab334707, 1:250; Anti-CPT1A,ab128568,1:500;Anti-PPARα antibody,ab8934,1:1000;Anti-STAT3 antibody, ab76315,1:250; Anti-Cardiac FABP antibody, ab174673,1:2000;Anti-Phospholipase A2 Antibody, ab23705, 1:250;Anti-NF-κB p105/p50 antibody,ab32360,1:500; Anti-COX2, ab15191,1:500). The primary antibody was firstly incubated, and then the secondary antibodies (Santa Cruz Biotechnology Inc., CA, U.S.A.) was added. After exposed by chemiluminescence developing agents, the protein levels and GAPDH in each sample were evaluated. The gel was scanned and the band densities were quantified. Protein expressions were normalized by the GAPDH band densities and then normalized by density in sham group to determine their concentrations.

Statistical analysis {#Sec9}
--------------------

Data were presented as mean ± standard deviation (mean ± SD). Differences among groups were analyzed by one-way analysis of variance (ANOVA) test. *P* values of smaller than 0.05 were considered as statistically significant. All statistical analyses were carried out using SPSS 17.0 software.

Results {#Sec10}
=======

Effects of DQP on cardiac functions {#Sec11}
-----------------------------------

Echocardiography results showed that LVEDd and LVESd in the model group increased by 53.52 % (*P* \< 0.01) and 156.73 % (*P* \< 0.01) as compared with those in the sham group, respectively (Fig. [1](#Fig1){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}). EF and FS in model group decreased by 49.96 % (*P \< 0.001*) and 58.30 % (*P \< 0.001*) respectively, suggesting that cardiac functions were severely impaired and CHD model was successfully induced. After treatment with DQP for 28 days, LVESd was reduced as compared with that in the model group. LVEDd wasn't affected by DQP. DQP could elevate the values of EF and FS by 43.00 % (*P* = 0.036) and 54.06 % (*P* = 0.041), respectively.Fig. 1DQP improved parameters of cardiac functions detected by echocardiography. Echocardiography results showed that LVEDd and LVESd in the model group increased significantly compared with those in the sham group. EF and FS in model group decreased respectively. DQP could reduce the LVESd while LVEDd wasn't affected by DQP. DQP also could upregulate EF and FS respectively, suggesting that DQP could improve cardiac function (\**P* \< 0.05, \*\**P* \< 0.01, other groups vs. model group, n = 8). **a** Cardiac functions in sham-operated group. **b** Cardiac functions were down-regulated in model group rats. **c** Positive Drug had no effects on the cardiac function. **d** DQP could significantly up-regulate the EF and FSTable 2Indicators of cardiac function in different groupsGroupShamModelControlDQPLVEDd(mm)5.651 ± 0.849\*\*8.675 ± 1.3359.043 ± 1.2548.812 ± 0.557LVEDs(mm)2.755 ± 0.848\*\*7.073 ± 1.7166.635 ± 0.769\*6.748 ± 0.677EF(%)81.604 ± 7.922\*\*40.831 ± 19.21232.327 ± 16.76558.391 ± 10.623\*FS(%)51.939 ± 9.322\*\*21.661 ± 11.78216.579 ± 9.46833.372 ± 6.696\*Compared with model group, *P* \< 0.05 \*, *P* \< 0.01\*\*

Effects of DQP on plasma lipid and lipoprotein levels {#Sec12}
-----------------------------------------------------

Compared with the sham group, levels of TC, TG, LDL and VLDL in the model group increased by 40.50 % (*P* = 0.032), 155.33 % (*P* = 0.004), 49.07 % (*P* = 0.031) and 170.52 % (*P* = 0.002), respectively. HDL level decreased by 46.11 % (*P* = 0.021) in model group compared with that in the sham group. After treatment with DQP, TG level rather than TC level in DQP group was reduced in DQP group compared with model group, suggesting that DQP has better efficacy on TG rather than TC. Levels of LDL and VLDL in the DQP group decreased by31.85 % (*P* = 0.015) and 56.49 % (*P* = 0.008) respectively, as compared with those in the model group. HDL level was up-regulated by 76.44 % (*P* = 0.026). These data suggested that DQP could regulate disorders of lipid metabolism in rats with CHD. The effects of Pravastatin on plasma lipid levels were similar with those of DQP (Table [3](#Tab3){ref-type="table"}).Table 3Indicators of plasma lipid and lipoprotein levels in different groupsGroupShamModelControlDQPTC(mmol/L)1.49 ± 0.35\*1.49 ± 0.35\*1.49 ± 0.35\*2.24 ± 0.28TG(mmol/L)1.05 ± 0.21\*\*2.68 ± 0.490.98 ± 0.51\*\*1.35 ± 0.37\*HDL(mmol/L)0.83 ± 0.18\*0.44 ± 0.260.97 ± 0.20\*0.78 ± 0.35\*LDL(mmol/L)0.50 ± 0.13\*0.75 ± 0.200.33 ± 0.16\*\*0.51 ± 0.11\*VLDL(mmol/L)0.46 ± 0.104\*\*1.25 ± 0.2380.45 ± 0.176\*\*0.54 ± 0.207\*\*Compared with model group, *P* \< 0.05 \*, *P* \< 0.01\*\*

Effects of DQP on key molecules involved in uptake of lipids {#Sec13}
------------------------------------------------------------

Expressions of LPL and CD36 were down-regulated by 30.65 % (*P* = 0.002) and 9.2 % (*P* = 0.034) in model group compared with those in the sham group, which suggested that uptake of FFA by cardiocytes was compromised in the model rats. After treatment with DQP, expressions of CD36 was up-regulated by 15.47 % (*P* = 0.03), compared with those in the model group (Table [4](#Tab4){ref-type="table"}). However, DQP showed no effect on expression of LPL in this study. Pravastatin showed no effect on the expressions of either LPL or CD36 (Table [4](#Tab4){ref-type="table"}).Table 4Key molecules involved in uptake of lipid in different groupsGroupShamModelControlDQPCD361.208 ± 0. 026\*1.097 ± 0.0681.235 ± 0.1491.267 ± 0.063\*LPL1.525 ± 0. 159\*\*1.194 ± 0.2470.893 ± 0.2261.158 ± 0.0247Compared with model group, *P* \< 0.05 \*, *P* \< 0.01\*\*

Effects of DQP on lipid transportations {#Sec14}
---------------------------------------

Expressions of ApoA-I and FABP in the model group (0.87 ± 0.04 and 0.90 ± 0.039) were down-regulated by 12.63 % (*P* = 0.016) and 10.00 % (*P* = 0.381), respectively, as compared with those in the sham group (1.00 ± 0.00, 1.00 ± 0.00). Level of CPT-1A, the key enzyme in lipid oxidation, decreased by 28.44 % (0.71 ± 0.064, *P* = 0.017) in the model group compared with those in the sham group (1.00 ± 0.00). Suppressed expressions of ApoA-I, FABP and CPT-1A suggested that transportation of fatty acids into mitochondria for oxidation was inhibited in CHD rats. In DQP group, expressions of ApoA-I (1.39 ± 0.081) and FABP (1.16 ± 0.189) were up-regulated by 59.53 % (*P* \< 0.01) and 28.97 % (*P* = 0.03) respectively, compared with those in the model group. Expression of CPT-1A also increased by 54.93 % (1.11 ± 0.192, *P* = 0.001), suggesting that DQP promoted the transportation of lipid into mitochondria for oxidation (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Effects of DQP on the myocardial concentrations of ApoA-I, FABP and CPT-1A. The results showed that expressions of ApoA-I and CPT-1A in the model group decreased compared with those in the sham group. Level of FABP showed no statistical difference between sham and model group. DQP could increase ApoA-I, FABP and CPT-1A levels. Pravastatin had similar effect as DQP. \*indicates *P* \< 0.05, \*\*indicates *P* \< 0.01. Levels in the model group (n = 6) were used as reference to calculate *P* values

Effects of DQP on inflammation pathway {#Sec15}
--------------------------------------

We then investigated changes of proteins in PLA2-COX-2 mediated inflammation pathway. Compared with the sham group (1.00 ± 0.00, 1.00 ± 0.00), expressions of PLA2 and COX-2 in the model group were up-regulated by 47.5 % (1.48 ± 0.225, *P* = 0.002) and 92.54 % (1.93 ± 0.856, *P* = 0.0196), respectively. DQP was shown to inhibit the activation of this pathway. Expressions of PLA2 and COX-2 in DQP group were down-regulated by 25.11 % (1.10 ± 0.225, *P* = 0.012) and 58.50 % (0.799 ± 0.156, *P* = 0.0039), compared with those in the model group. Control drug had no significant effect on the expression of PLA2 or COX-2 (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Effects of DQP on the myocardial concentrations of PLA2 and COX2. Western blot results showed that compared with the sham group, expressions of PLA2 and COX-2 in the model group were up-regulated. Expressions of PLA2 and COX-2 in DQP group were down-regulated significantly, compared with those in the model group. Control drug had no significant effect on the expression of PLA2 or COX-2. \**P* \< 0.05, \*\**P* \< 0.01. Protein expression levels in the model group (n = 6) were used as reference to calculate *P* values

Effects of DQP on PPARα signaling pathway {#Sec16}
-----------------------------------------

NF-κB and STAT3 are signal transduction factors that are important in promoting ventricular hypertrophy. Compared with the sham group (1.00 ± 0.00, 1.00 ± 0.00), expressions of NF-κB and STAT3 in the model group were up-regulated by 35.75 % (1.358 ± 0.212, *P* = 0.074) and 113.9 % (2.14 ± 0.354, *P* \< 0.01), respectively. Expression of PPARα, the critical regulator of lipid metabolism, was down-regulated by 24.25 % (0.76 ± 0.162, *P* = 0.031) in the model group compared with that in the sham group. After treatment with DQP, NF-κB was inhibited and PPARα was activated. Expression of NF-κB was down-regulated by 56.2 % (0.59 ± 0.131, *P* = 0.0004) in DQP group compared with that in the model group, which suggested that the anti-inflammatory effect of DQP may be mediated by inhibition NF-κB. Compared with the model group, PPARα level increased by 141.31 % (1.83 ± 0.729, *P \< 0.001*) in DQP group, demonstrating that DQP is a potent agonist of PPARα (Fig. [4](#Fig4){ref-type="fig"}). DQP showed no effect on STAT3 expression.Fig. 4Effects of DQP on the levels of NF-κB, STAT3 and PPARα. Western blot showed that compared with the sham group, expressions of NF-κB and STAT3 in the model group were up-regulated (*P* = 0.074, P \< 0.01). Expression of PPARα was down-regulated (*P* = 0.031) in the model group compared with that in the sham group. DQP could inhibit NF-κB level but showed no effect on STAT3 expression. Pravastatin had no effect on expression of STAT3 either. Compared with the model group, PPARα level increased in DQP group. \**P* \< 0.05, \*\**P* \< 0.01. Levels in the model group (n = 6) were used as reference to calculate *P* values

Discussion {#Sec17}
==========

Traditional Chinese medicine has been widely used in the prevention and treatment of CHD for thousands of years \[[@CR33]\]. DQP is one of the most commonly prescribed formulas and has been shown to be effective in treating CHD \[[@CR34]\]. In this study, we investigated the pharmacological mechanisms of DQP in a rat model of CHD induced by ligation of coronary artery. Our major findings are as follows: 1), DQP can effectively improve the cardiac functions and regulate plasma lipids levels in rats with CHD. 2), DQP promotes lipid oxidation in cardiomyocytes by up-regulating expressions of molecules involved in uptake and transportation of lipids, which include ApoA-I, CD36 and CPT-1A. 3), the anti-inflammatory effect of DQP may be mediated by its inhibition on PLA2-COX-2 pathway. DQP down-regulates NF-κB expression, without affecting STAT3 expression. 4), DQP has the similar effect with that of PPARα agonist, and activation of PPARα might be the major mechanism by which DQP regulates lipid metabolism and inhibits inflammation.

It is reported that dyslipidemia is a high risk factor for CHD \[[@CR35]\]. Cholesterol, triglycerides, LDL and HDL are the major components of plasma lipids that play critical roles in the development of CHD. Total blood cholesterol and LDL increase CHD risk in an independent manner \[[@CR7], [@CR36]\]. Elevated level of TG affects the process of reverse cholesterol transportation by HDL \[[@CR37], [@CR38]\]. It's reported that an increase of 23 mg/dl in TG content will lead to 20 % increased risk of developing CHD \[[@CR39]\]. Contrary to the effects of TG and LDL, HDL is considered to be a protective factor against development of CHD. High level of HDL is related with decreased risk of CHD \[[@CR40]\]. HDL and its major component, ApoA-I, can promote reversal cholesterol transport and regress formation of atherosclerotic plaques \[[@CR41], [@CR42]\]. HDL can also inhibit inflammation by down-regulating expression of vascular cell adhesion molecule-1 \[[@CR43]\]. In this study, we found that plasma levels of TG, LDL and VLDL increased, while levels of ApoA-I and HDL decreased in model group. Furthermore, level of lipoprotein lipase (LPL), the key enzyme in regulating lipid and lipoprotein metabolism, also decreased in the model group. Treatment with DQP could effectively regulate disorders in lipid metabolism, as was evidenced by decreased plasma levels of TG, LDL and increased HDL level in DQP group compared with the model group. However, DQP didn't show effect on expression of LPL. Positive control drug showed similar effect on lipids levels as that of DQP. However, positive control drug failed to improve cardiac functions, indicating that DQP has advantage over control drug in the treatment of cardiovascular disease.

The effect of DQP on lipid metabolism pathway was then examined. Fatty acid translocase/cluster of differentiation protein (FAT/CD36) plays an important role in lipid metabolism by transporting long chain fatty acid into mitochondria \[[@CR44]--[@CR47]\]. Overexpression of FAT/CD36 promotes oxidation of fatty acid and lipoproteins \[[@CR48]\]. Plasma fatty acids are translocated into cytoplasm of myocardial cells by binding with fatty acid binding protein (FABP) on the membrane, and are further transferred into mitochondria catalyzed by the enzyme CPT-I. Oxidation of fatty acids in mitochondria provides the majority of energy for heart contraction and CPT-I is the critical enzyme in oxidation process \[[@CR49]\]. CPT-1A is one of the most abundant subtypes of CPT-I. In this study, expressions of FABP, CD36 and CPT-1A in the heart tissues of model rats were significantly reduced, which suggested that uptake and transportation of lipids were deregulated under myocardial ischemic conditions. The disorder of lipid transportation will lead to build-up of lipids in the plasma as well as shortage of energy supplies. After treatment with DQP, CD36 and CPT-1A levels were considerable up-regulated, compared with those in the model group, demonstrating that DQP has the effect of promoting lipid uptake by cardiac cells.

In addition to disorders of lipid metabolism, arachidonic acids (AA)-mediated inflammation is also an important pathological mechanism of cardiovascular diseases \[[@CR25]\]. We further explored the effect of DQP on inflammation pathway. Under normal conditions, most of theAA exist in membranes as the components of phospholipids. When cell is under ischemic or inflammatory stimuli, phospholipid lipase A2 (PLA2) will catalytically hydrolyse phospholipids and release AA into cytoplasm. AA are subsequently converted to different metabolites by a series of enzymes. COXs are a group of enzymes that convert AA into prostaglandins (PGs) and thromboxanes (TXs), which are the major best-known products of AA. PGs and TXs mediate myocardial damage, apoptosis, fibrosis and progression of CHD \[[@CR50]\]. Therefore, inhibiting activities of COXs has become a new strategy for the management of CHD \[[@CR18]\]. Studies have shown that selective COX-2 inhibitors can inhibit vascular inflammation, reduce monocyte infiltration, increase production of NO, attenuate atherosclerosis and stabilize plaques, thereby reducing incidence of cardiovascular events \[[@CR51]\]. COX-2 inhibitors can also improve cardiac function under myocardial infarction conditions \[[@CR18]\]. In this study, we found that AA-mediated inflammation pathway was activated in the model group, as both PLA2 and COX-2 were over-expressed in ischemic heart tissues. DQP treatment significantly inhibited expressions of PLA2 and COX-2, indicating that DQP has both lipid-lowing and anti-inflammatory effects.

DQP also exerts its cardioprotective effects by acting on PPARα. There are three subtypes of PPAR: α, β(δ) and γ \[[@CR52]\]. PPARα is mainly expressed in metabolically active tissues, such as heart, liver, kidney, etc. As a important regulator of metabolism, PPARα has a central coordinating role in the regulation of fatty acid oxidation, lipoprotein metabolism, inflammation and vascular responses \[[@CR53]--[@CR55]\]. It was reported that under myocardial ischemic circumstances, mRNA expression of PPARα was reduced and FFA uptake was decreased, aggravating cardiac ischemic damage \[[@CR56]\]. All these evidences support a linkage between PPARα and cardiovascular diseases. PPARα also exerts anti-inflammatory effect by inhibiting NF-κB mediated pathway and down-regulating secretion of pro-inflammatory factors, such as IL-6, TNF-α and COX-2 \[[@CR57]\]. Our study showed that in ischemic heart tissue, expression of PPARα was down-regulated and expressions of COX-2 and NF-κB were up-regulated, indicating that inflammation pathway was activated under ischemic conditions. DQP can effectively inhibit inflammation by reducing expressions of NF-κB and COX-2. More importantly, PPARα expression was significantly up-regulated in DQP-treated group compared with the model group, demonstrating that DQP is a potential effective PPARα agonist in the treatment of CHD.

Conclusions {#Sec18}
===========

DQP has regulatory effect on lipid uptake-transport-metabolism pathway in myocardial cells of rats with heart failure, and the effect is achieved mainly by activating ApoA-I-CD36-CPT-1A molecules. The anti-inflammatory effect of DQP is probably achieved by inhibiting NF-κB in PLA2-COXs mediated inflammation pathway (Fig. [5](#Fig5){ref-type="fig"}). Interestingly, DQP can up-regulate expression of PPARα significantly. This study provides experimental evidence for the clinical application of DQP in the treatment of CHD.Fig. 5Potential mechanism of DQP efficacy on CHD rats. DQP has regulatory effect on lipid uptake-transport-metabolism pathway in myocardial cells of rats with heart failure. Moreover, DQP can up-regulate expression of PPARα significantly. The anti-inflammatory effect of DQP is probably achieved by inhibiting NF-κB in PLA2-COXs mediated inflammation pathway
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